Saturday, 7 November 2026
GP isotretinoin bid rejected, Tumours reported after Zolgensma, US Medicare payment cuts
- 01
TGA provisionally rejects broader GP prescribing of isotretinoin
The TGA has issued an interim decision rejecting a bid to allow GPs to prescribe isotretinoin, leaving prescribing restricted to specialist physicians and dermatologists. The regulator cited teratogenicity, clinical complexity, insufficient safeguards and a lack of evidence that the change would maintain current safety standards or address a significant access barrier. It also raised concerns about inappropriate prescribing for mild acne or off-label uses and misuse through low-engagement telehealth and cosmetic services. The RACGP called the decision deeply disappointing, disputed the assessment of GP expertise and patient access barriers, and said it would make a submission. Public consultation on the interim decision closes on 4 December.
via RACGP newsGP
- 02
Nine tumours reported after Zolgensma, two with vector integration
Nine people with spinal muscular atrophy developed tumours after receiving Novartis’ gene therapy Zolgensma, including two cases with evidence that the viral vector integrated into patient DNA. The disclosure added seven cases to two previously reported in 2023 and 2025, although Zolgensma was not definitively linked to the earlier tumours. Cure SMA said three patients’ tumours had been tested and one case appeared unrelated to the therapy. Novartis said it notified health authorities after each case and would work with them on next steps; both patients with vector integration were treated and remain under monitoring. About 6,000 people have received Zolgensma, whose prescribing information already warns of the theoretical risk of vector integration into patient DNA.
via BioPharma Dive
- 03
US Medicare finalises major 340B cuts and site-neutral expansion
US Medicare will cut 340B drug reimbursements and expand site-neutral payments under a final rule taking effect in 2027. Medicare will reimburse 340B participants at the average sales price minus 28%, which the Centers for Medicare and Medicaid Services estimated would reduce drug spending by about $5.5 billion next year. Imaging without contrast, including CT, MRI, X-ray and bone density scans, will receive the same payment in hospital-owned outpatient departments and freestanding physician offices, with projected taxpayer and beneficiary savings exceeding $9 billion over a decade. Hospital outpatient departments and ambulatory surgery centres will receive a 2.3% payment increase, but the American Hospital Association said the rise was inadequate and the 340B cuts would place further pressure on hospitals.
via MedTech Dive · also covered by BioPharma Dive
- 04
Hackers alter refrigeration controls at French blood service sites
Hackers raised temperature and defrost thresholds to “very high levels” in cold rooms at three French blood preparation or distribution sites. France’s national blood service, Établissement français du sang, said the breach occurred through a refrigeration monitoring and control supplier, but blood stocks were unaffected. The cold rooms normally operated at −30°C. Similar cyberattacks manipulated supermarket refrigeration systems in more than 10 European countries, including France and the UK, although investigators had not established whether the incidents were linked.
via BMJ
- 05
ACRRM revenue and membership grew as grant income surged
ACRRM’s revenue rose 28% to $112.2 million in 2025–26, with Department of Health and Ageing grants for GP training accounting for $98.2 million, or 87.5%. Membership increased 6.4% to 7652, while fellow numbers rose 5.5% to 2414 and medical educator numbers climbed almost 24% to 203. The college conducted 1104 summative assessments, with pass rates remaining at 84%, and secured funding to deliver rural generalist training through to 2030. ACRRM recorded a surplus of about $3.05 million, although cash holdings fell from $70.3 million to $58.3 million and operating cash flow shifted from positive $14.1 million to negative $9.8 million. The growth followed the recognition of rural generalist medicine as a medical specialty in September 2025.
- 06
Government plans competitive retender of NHS data platform contract
The UK government is planning to put its NHS Federated Data Platform contract with US technology company Palantir out to competitive tender, according to The BMJ. The retender would require Palantir to rebid against UK-based competitors. Department of Health and Social Care officials have approached a handful of British companies about their capacity to run the platform, an anonymous industry source told the publication. The government is also expected to extend the £182 million contract by two years to minimise disruption during the retendering process.
via BMJ
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.